Don’t just choose a CDMO. Choose a co-pilot.

The active pharmaceutical ingredient (API) manufacturing landscape is more demanding than ever. Drug developers face increasing molecular complexity, more stringent regulatory oversight, and rising pressure to deliver high-quality products at speed. In this environment, choosing the right contract development and manufacturing organization (CDMO) partner is not just important. It is essential.

Beyond scientific capabilities, developers now expect their CDMO to act as an extension of their own team. That means not only bringing technical depth and proven reliability, but also working in a way that reduces friction. The most valuable CDMOs make complex programs easier to manage by being responsive, easy to engage with, and fully aligned with their partners’ objectives from day one.

A capable CDMO offers more than infrastructure. It brings together quality, trust, and the flexibility to support a range of modalities. At Axplora, our customers rely on a strong track record in regulatory compliance and delivery. Our quality systems are built to meet global standards, with the most recent ANSM inspection completed in 2025.

Reliability means more than consistent output. It requires having the people, systems, and mindset to proactively solve challenges during development, scale-up, or tech transfer. That is especially important in today’s landscape, where projects often involve specialized molecules like peptides or antibody-drug conjugates (ADCs). Over the last five years, Axplora has successfully validated more than 25 process steps across its sites, demonstrating the rigor and reliability needed to support complex API programs.

Axplora’s network spans Europe and India, providing access to advanced technologies such as preparative chromatography, peptide purification, and electrochemistry. This global presence allows us to assign projects based on molecule type, regulatory requirements, and timelines, offering greater flexibility and security of supply.

Our ability to scale across five CDMO sites gives us the flexibility to meet customers where they are. Whether a project involves small-scale development or commercial production of complex modalities, we can provide a tailored, efficient solution. This reach is strengthened by ongoing investment in infrastructure, technology, and sustainability, helping us stay responsive to emerging needs and support projects through every stage of development.

Ease of collaboration is often overlooked but critical in CDMO selection. At Axplora, we prioritize early engagement, open communication, and strong internal coordination. Customers value how straightforward it is to work with our teams and how quickly we respond when timelines shift or project needs evolve. In fact, 100% of our customers have said they would choose to work with us again, and many of our key relationships span more than 10 years.

Our integrated project management and development teams work closely to reduce friction in tech transfers and ensure alignment at every step. For ADC drug substances, we have achieved timelines as short as four months from bench to GLP manufacturing. This kind of agility helps maintain momentum and avoids delays that can arise when silos form between partners.

Scaling a complex molecule is not just a technical milestone. It is a joint effort that involves knowledge sharing, timeline planning, and a clear regulatory strategy. At Axplora, we work with customers from the earliest stages to define goals, assess risks, and ensure readiness for scale-up and submission.

Our collaborative model helps drug developers move faster and with greater confidence, supported by expert teams that are invested in their success.

In a high-stakes landscape, your CDMO should be more than a vendor. They should be mission control. Contact us and let’s take your project to the next level.